Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer

Thyroid cancer is the most frequent endocrine tumor. However, in locally advanced or metastatic disease we have only two types of treatment at our disposal: radioactive iodine (RAI) when the disease is RAI‐sensitive and multikinase inhibitors (MKIs), lenvatinib and sorafenib, when the disease become...

Descripción completa

Detalles Bibliográficos
Autor principal: Herranz, Urbano Anido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537052/
https://www.ncbi.nlm.nih.gov/pubmed/36202606
http://dx.doi.org/10.1002/cam4.5105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537052/
https://www.ncbi.nlm.nih.gov/pubmed/36202606
http://dx.doi.org/10.1002/cam4.5105

Ejemplares similares